The aim of the project is to offer a new therapeutic option for the inflammation associated with cystic fibrosis. In fact, it is not yet known whether that harmful process will be solved by the CFTR’s correctors and potentiators; most likely effective anti-inflammatory drugs are to be used along with the modulators. Recently, the activity of the enzyme histone deacetylase 6 (HDAC6) has been related to crucial pathogenetic mechanisms associated with both the onset of dysregulated lung inflammation and fibrotic processes in CF. HDAC6 represents a new biological target, whose function is inhibited through some already known small molecules, endowed with high power and selectivity. Through a multidisciplinary approach (medicinal chemistry, pharmaceuticals, biochemistry and molecular biology), the project intends to select the most promising inhibitory molecules, synthesize them, test them in vitro and also vivo in animal models of lung infection and CF disease. The prospect is to obtain a new compound capable of regulating the inflammatory process in cystic fibrosis.